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Fibronectin promotes the proliferation of cytotoxic T lymphocytes
generated from cancer patients
S Mizobata, H Tanimura, H Yamaue, M Tani, T Tsunoda, M Iwahashi, K Noguchi,
N Nishimoto, T Hotta and K Arii
Second Department ofSurgery, Wakayama Medical School, 27-Shichibancho, Wakayama 640, Japan.
Summary We studied whether fibronectin (FN) enhances the activity of autologous tumour-reactive cytotoxic
T lymphocytes (CTLs) generated from cancer patients. The proliferation of CTLs stimulated by immobilised
anti-CD3 monoclonal antibody and interleukin 2 (IL-2) was enhanced three or four times by immobilised FN,
whereas soluble FN did not alter the DNA synthesis of CTLs. Moreover, the cytotoxic activity of CTLs was
augmented by FN stimulation against autologous tumour cells [4 h 51Cr release assay: FN(+) 16.7+4.7% vs
FN (-) 11.8+3.1%; 16 h 51Cr release assay: FN(+) 24.8+4.7% vs FN (-) 16.5+5.7%, P<0.05]. The major
cell surface phenotype of CTLs with FN was CD3+, CD4+ and CD25+ in 6 weeks' culture. Cytotoxicity
against autologous tumour cells was inhibited by anti-HLA class I monoclonal antibody (MAb). The
autologous tumour-killing activity of CTLs was suppressed by the elimination of CD4+ cells. Moreover, the
cytokine production of CTLs was augmented by FN stimulation. Especially, the production of IL-2, interferon
gamma (IFN-y), and granulocyte -macrophage colony-stimulating factor (GM-CSF) was significantly
augmented by FN stimulation (P<0.05). Thus, CTLs generated by FN might have both killer and helper
functions, since they could lyse autologous tumour cells and secrete various cytokines, including IL-2.
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The adoptive immunotherapy (AIT) for advanced cancer
patients with lymphokine-activated killer (LAK) cells or
tumour-infiltrating lymphocytes (TILs) has been considered
to be a valuable strategy in cancer therapy. However, the
initially encouraging results from Rosenberg, et al. (1987,
1988) have failed to translate into a reliable approach to
treatment when studied by other authors. For the improve-
ment of clinical efficacy, many studies of effector cells and
their culture methods have been performed. We have
reported that AIT, using TILs activated by interleukin 2
(IL-2) and interleukin 4 (IL-4), is considered to be useful in
cancer patients with malignant ascites (Yamaue et al., 1990;
Tsunoda et al., 1991, 1992). However, TILs cannot be
induced in all the patients, and they usually require a long
culture period.
We, therefore, studied cytotoxic T lymphocytes (CTLs)
induced by autologous mixed lymphocyte tumour culture
(AMLTC), and demonstrated that CD4+ CTLs generated by
immobilised anti-CD3 monoclonal antibody (MAb) had both
helper and killer functions, and they were effective for AIT in
cancer patients (Tani et al., 1995).
Fibronectin (FN) is a one of the macromolecules that
promote cell adhesion, cell migration and differentiation.
Recently, FN was reported to augment the proliferation of
human peripheral blood lymphocytes (PBLs) by combination
with immobilised anti-CD3 MAb (Shimizu et al., 1990;
Matsubayashi et al., 1989; Cardarelli et al., 1991; Davis et al.,
1990). However, there is no report that clarifies whether FN
augments the proliferation and the activation of CTLs
induced by AMLTC from cancer patients.
The present study was designed to clarify whether FN
promotes the proliferation and activation of CTLs, and to
present the functional characteristics of CTLs stimulated by
FN.
Materials and methods
Patients
Peripheral blood mononuclear cells (PBMCs) were obtained
from 16 patients with malignant diseases (one thyroid cancer,
four gastric cancer, one duodenal cancer, one colonic cancer,
three gallbladder cancer, one gallbladder carcinosarcoma, one
ovarian cancer, one malignant methothelioma of the
peritoneum, one leiomyosarcoma of retroperitoneal region,
one angiosarcoma and one adenocarcinoma of unknown
origin) (Table I).
AMLTC
PBMCs separated from heparinised peripheral blood were
obtained from cancer patients by Ficoll-Hypaque (Pharma-
cia, Uppsala, Sweden) gradient centrifugation (400 g, 30 min,
20°C). The PBMCs, suspended at 2 x 106 ml-1 in RPMI-1640
medium (Nissui, Tokyo, Japan) supplemented with 2 mM L-
glutamine, 100 U ml- penicillin, 100 Mg ml- streptomycin,
50 giM 2-mercaptoethanol and 5% heat-inactivated human
AB serum (Nipro, Osaka, Japan) (complete medium), were
used as responder cells (R).
Fresh excised tumour tissues were processed by enzymatic
digestion as described previously (Tani et al., 1995; Yamaue
et al., 1991; Yamaue et al., 1992; Iwahashi et al., 1992).
Briefly, tumour tissues were dissected into pieces smaller
than 2 mm3 and these were immersed in medium containing
collagenase (2 mg ml-', type V-S; Sigma, St Louis, MO,
USA), hyaluronidase (10 U ml-', type IV-S; Sigma) and
DNAase-I (0.4 mg ml-'; Sigma). After 40 min incubation,
cells obtained from solid-tumour specimens and ascites were
centrifuged on Ficoll-Hypaque gradients at 400 g for 30 min,
and the cells were centrifuged on discontinuous gradients
consisting of 100% and 75% Ficoll-Hypaque at 400 g for
30 min. The tumour-cell-rich fraction was then layered on
discontinuous gradients containing 25%, 15% and 10%
Percoll (Pharmacia) and centrifuged at 25 g for 7 min.
Tumour cells depleted of lymphoid cells were collected from
the bottom and from the 25% interface, and were then
washed and suspended in complete medium. These
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Table I Materials and methods
Assay
Proliferation
Case Diagnosis Age Sex assay Phenotype CRA Cytokine
1 Thyroid cancer 81 F Yes No No No
2 Gastric cancer 62 F Yes Yes Yes No
3 Gastric cancer 40 M Yes No No No
4 Gastric cancer 47 M Yes No No No
5 Gastric cancer 38 M No Yes Yes No
6 Duodenal cancer 59 M Yes No Yes No
7 Colonic cancer 61 F Yes Yes Yes No
8 Gallbladder cancer 56 F No Yes Yes Yes
9 Gallbladder cancer 59 F No Yes Yes Yes
10 Gallbladder cancer 70 F No No No Yes
11 Gallbladder carcinosarcoma 58 M Yes No No No
12 Ovarian cancer 64 F Yes No No Yes
13 Methothelioma 53 M No Yes Yes Yes
14 Leiomyosarcoma 52 F Yes No Yes No
15 Angiosarcoma 78 F Yes No No No
16 Adenocarcinoma of unknown origin 71 M Yes No No No
CRA, 51Cr release assay.
autologous tumour cells, treated with 50 Hg ml-1 mitomycin
C (MMC; Kyowa Hakko, Tokyo, Japan) at 37°C for
40 min, were used as stimulator cells (S). PBMCs were
cultured with autologous tumour cells for 5 days at 37°C in
a humidified 5% carbon dioxide atmosphere, at the optimal
ratio (PBMC/tumour cells = 100/1) (Tani et al., 1995).
Preparation of anti-CD3 MAb andfibronectin-coated
microtitre plates
Culture wells were coated for 4 h at room temperature with
10 Mg ml-' of anti-CD3 MAb (muromonab-CD3, IgG2a,
Orthoclone) in 0.05 M Tris/PBS (pH 9.2) and washed twice
with complete medium and once withmediumcontaining 0.5%
human AB serum. After washing twice with PBS, 100 Ml ml-'
PBS containing the indicated concentrations of human
fibronectin (Upstate Biotechnology Inc., USA) was placed in
each well and incubated at room temperature for 4 h. Then, the
wells were washed twice with complete medium.
Generation of CTLs induced by AMLTC
CTLs induced by AMLTC were activated in anti-CD3 MAb-
coated wells (with or without immobilised FN) at a
concentration of 1 x 105 per well in complete medium
combined with 20, 100, 250 and 1000 IU ml-1 IL-2 (S6820;
Shionogi, Osaka, Japan) or without IL-2.
DNA synthesis in CTLs
DNA synthesis in CTLs was measured by determining
[3H]thymidine incorporation ([3H]TdR; NEN, Boston, MA,
USA). CTLs (5 x 105 ml-') were cultured for 3 days in anti-
CD3 MAb-coated flat-bottomed microtitre plates (Falcon
3072; Lincoln, NJ, USA) (with or without immobilised FN)
with indicated IL-2 concentration, pulse with 37.5 kBq per
well of [3H]TdR during the last 16 h of culture, and
harvested. Radioactivity was determined with a liquid
scintillator. The experiment was performed in triplicate.
Cytotoxic assay
The 51Cr-release assays (CRA) were performed to assess killer
cell cytotoxicity, as described (Iwahashi et al., 1992; Yamaue
et al., 1987, 1989). The target cells were used: autologous
tumour cells, KATO-III; a gastric carcinoma cell line, and
K562; a promyelocytic leukaemia cell line. Target cells were
labelled with 3.7 MBq ofNa25"CrO4 for 1 h at 37°C and then
washed; 100 Mil of 51Cr-labelled tumour cells (1 x 105 ml-')
were added to 100 Yl of effector cells in 96-well round-
bottomed microtitre plates (Corning, NY, USA, no. 2580).
The effector to target ratio was fixed at 15:1, and 30:1, since
the data for other ratios were related to data for ratios fixed
at 15:1 and 30:1. The experiment was performed in triplicate.
After 4 h or 16 h incubation, the radioactivity of the
supernatants was determined with a gamma counter (ARC-
300, Aloka). The spontaneous release did not exceed 30% for
autologous tumour cells and 15% for established tumour cell
lines, of maximum release obtained by adding 1 N
hydrochloric acid. The background (spontaneous) release of
autologous tumour cells was 534+291 c.p.m. and
722+437 c.p.m. in 4 h and 16 h 5'Cr-release assay respec-
tively. The percentage specific cytotoxicity was calculated as
follows (all 51Cr values in c.p.m.):
Test51Cr release - spontaneous release 100
Maximum release - spontaneous release
Flow cytometric analysis ofsurface antigens
The surface antigens of the CTLs were examined by flow
cytometry, using FITC- orPE-labelled anti-human CD3, CD4,
CD8, CD16, CD25 (Becton-Dickinson, Mountain View, CA,
USA) and Mik-f,l (anti-IL-2-receptor #-chain, Nichirei,
Tokyo, Japan) MAb. The CTLs (1 x 107ml-') were suspended
in Ca2+-Mg2+-free PBS (Nissui) containing 0.1% bovine
serumalbumin (BSA). MAb(100 Ml ml-')wasaddedto thecell
suspension, which was then incubated for 30 min at 4°C,
washed twice with cold Ca2+- and Mg2"-free PBS, and
resuspended in PBS/0.1% sodium nitrite for flow cytometric
examination, including blue laser with an excitation of 15 mW
at 488 nm (FACStar, Becton Dickinson). Data were gathered
from 10 000 cells using a live gate.
Analysis ofeffector cell phenotype by negative selection
methods
Negative selection by immunomagnetic beads was performed
as described (Tani et al., 1995; Iwahashi et al., 1992).
Activated CTLs (1 x 107 ml-') from two patients (one colonic
cancer and one gallbladder cancer) were suspended in RPMI-
1640 containing immunomagnetic beads coated with
500 MI ml-' of (M-450; Dynal, Oslo, Norway) sheep IgG,
anti-CD4 or anti-CD8 MAb (IgG), and were incubated at
4°C for 30 min with occasional shaking. Rosette-forming
cells were then removed with a flat cobalt samarium magnet.
Non-rosetted cells were washed, suspended in complete
medium containing 10% foetal bovine serum (FBS), and
assessed for cytotoxic activity.CD4+CTL stmulated by fibronectin
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Examination ofmajor-histocompatibility complex restriction
We determined the major histocompatibility complex
(MHC) restriction of the activated CTLs by using MAb.
In CRA, anti-HLA-class I MAb (mouse IgG2a, IOT 2;
Cosmo, Tokyo, Japan), anti-HLA-DR MAb (IOT 2a;
Cosmo, Tokyo, Japan) or mouse IgG (Cappel, Organou
Technika, Durham, NC, USA) as a control antibody, was
added to the microtitre plate, at a final concentration of
5 ,ug ml-', which was enough for inhibition in a positive
control for these antibodies (Tani et al., 1995; Malissen et
al., 1982).
Cytokine assay in the supernatants
CTLs (5 x 105 ml-', 200 Ml per well), immediately after
AMLTC, were cultured in anti-CD3 MAb-coated 96-well
flat-bottomed microtitre plates (with or without immobilised
fibronectin) at 37°C in a humidified 5% carbon dioxide
atmosphere for 24 h without further tumour cell stimulation,
and the supernatant was collected after centrifugation.
Cytokine activity was assayed by using enzyme-linked
immunosorbent assay (ELISA) kits (IL-2, Intertest-2X,
Genzyme, Cambridge, MA, USA; IFN-y, GM-CSF and IL-
4, Medgenix Diagnostics, Fleurus, Belgium; IL-6, Toray-Fuji
Bionics, Tokyo, Japan).
Statistical analysis
Significant differences were determined by Wilcoxon's test. A
P-value below0.05 wasconsidered to bestatistically significant.
Each value is expressed as the mean+standard error.
Results
Proliferation of CTL by immobilised FN
As shown in Figure 1, immobilised FN (ranged from 2-
50 Mg ml-') augmented the DNA synthesis of CTLs
stimulated by immobilised anti-CD3 MAb and IL-2.
Since we have been culturing CTLs stimulated by
10 pg ml-' immobilised anti-CD3 MAb and 250 IU ml-'
IL-2 for adoptive immunotherapy of cancer patients (Tani et
al., 1995), we examined the effect of immobilised FN on
CTLs stimulated by 10 ,ug ml-' immobilised anti-CD3 MAb
and 250 IU ml-' IL-2 (Table II). The enhancement of
proliferation of CTLs was observed by immobilised FN at
concentrations of 2-50 pg ml-' (P<0.05). The proliferative
effect of immobilised FN (ranged from 2-50 Mg ml-') was
observed at a significant level (P<0.05). The proliferative
effect of 10 Mg ml-' immobilised FN was significantly higher
compared with those of other doses of immobilised FN.
Therefore, the dose of 10 Mg ml-' FN was used for all
subsequent studies.
Moreover, the cell numbers of CTLs stimulated by
immobilised FN was three or four times higher than CTLs
stimulated without FN (Figure 2). On the other hand, the
soluble FN did not alter the proliferation and cell numbers of
CTLs stimulated by immobilised anti-CD3 MAb and
250 IU ml-' of IL-2 (data not shown).
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Figure 1 Dose titration of immobilised fibronectin on the
proliferation of CTL. CTL (5x i05mI-F) were stimulated with
immobilised fibronectin (ranging from 2 to 50 gml-),
immobilised anti-CD3 MAb (10pgml-') and IL-2 (ranging
from 0 to 1OOOIUml-1). Control means CTL stimulated without
fibronectin and anti-CD3 MAb.
Cytotoxicity of CTLs generated by immobilised FN
In all cases that we could examine, the cytotoxic activity of
CTLs was augmented by FN stimulation against autologous
tumour cells, by 4 h and 16 h CRA respectively. On the other
hand, the cytotoxic activity of CTLs against other established
tumour cell lines did not show a tendency to be augmented
by FN stimulation (Table III).
Surface phenotypes of CTLs generated by immobilised FN
The phenotypes of the CTLs (two gastric cancer, one colonic
cancer, one gallbladder cancer and one malignant methothe-
lioma of the peritoneum) were determined by flow cytometry.
The major cell surface phenotype of FN-stimulated CTLs
was CD3+, CD4+ and CD25+ (Table IV).
MHC restriction of CTLs generated by immobilised FN
As shown in Table V, the autologous tumour killing activity
was suppressed by anti-HLA class I MAb, whereas it was not
altered by anti-HLA-DR MAb. These findings indicate that
HLA class I restricted CTLs were generated by immobilised
FN. We examined the phenotypes of these CTLs by a
negative selection method employing immunomagneticCD4'CTL stimulated byfibronectin
S Mizobata et at
1601
Table II DNA synthesis of CTL
FN (jggml-1)
Case Control 0 2 5 10 50
Case 1 45 638 68 884 76328 73 877 74082 73854
Case2 11576 31985 35055 35625 35 156 34605
Case3 92191 193500 207787 201810 220029 213013
Case4 76 113 104794 116151 124 126 122337 118399
Case6 57598 119668 145 127 156815 156404 149251
Case7 23 705 35499 39090 38657 40341 40065
Case 15 30094 55542 65 896 67479 68 798 68 573
Case 16 12843 33 838 42841 46603 46900 43314
Mean 43719 80457 91034* 93124* 95506* 92009*
s.e. 10494 19914 21626 21669 23205 22407
[3H]Td R incorporation (c.p.m.). CTLs (5 x i05 ml-) were stimulated with immobilised fibronectin (ranged from 2-50 mgml-'), immobilised
anti-CD3 MAb (10 gml-') and IL-2, 250IUml-'. Control shows CTL stimulated without fibronectin and anti-CD3 MAb. *P< 0.05, compared
with control and FN, 0Mgml- .
(x 106) Case 3 (x 106) Case 6 (x 106) Case 7
Duodenal cancer
CD3+FN
10 20
Culture day
30 0
Colon cancer
CD3+FN
10 20 30
Figure 2 The growth curve of CTL. The cell numbers were counted in three patients. The cell numbers at the start of culture were
3 x 106. 0, CTL stimulated with immobilised fibronectin, immobilised anti-CD3 MAb and IL-2, 250IUml-'. 0, CTL stimulated
without immobilised fibronectin.
Table III Cytotoxicity of activated CTL
Cx(%)a
AUTO K562 KATO-III
4h 16h 4h 16h 4h 16h
FNstimulation (-) (+) (-) (+) (-) (+) (-) (+) (-) (+) (-) (+)
Case2 (day42) 25.4 40.5 39.5 47.5 53.4 61.1
CaseS (day21) 5.1 8.2 8.8 17.8 2.0 1.7 8.3 4.9 18.6 17.3 48.9 45.3
Case6 (day21) 8.1 8.6 7.8 15.8 33.2 37.1 39.6 41.4
Case7 (day42) 6.6 10.6 27.7 34.0 26.9 33.0 34.9 35.5
Case8 (day28) 5.9 8.2 13.2 22.8 4.3 4.3 11.6 11.6 26.2 23.9 64.2 58.2
Case9 (day28) 3.0 13.6 20.6 26.5 15.0 11.5 31.1 27.2 24.5 24.2 53.9 46.1
Case 13 (day28) 22.0 28.3 2.8 1.9 6.2 5.3 24.6 24.1
Case 14 (day21) 9.5 12.9 5.3 4.6 5.5 9.8 31.3 24.8
Mean 10.7 16.4* 15.6 23.4* 5.8 4.8 17.0 14.5 22.5 24.7 43.8 42.0
s.e. 2.9 4.1 3.7 3.2 2.3 1.7 7.1 6.6 4.2 4.9 4.7 4.8
The cytotoxic activity of CTL against autologous tumours was augmented by FNstimulation (*P<0.05). Activated CTL were generated by
stimulation with 10 gml-l immobilised anti-CD3 MAb, 250IUml IL-2 with or without 10igml' immobilised fibronectin. aCytotoxicity was
measured by 4h and 16h 51Cr-release assay at the ratio of 15:1 in triplicate.
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Table IV Phenotypic analysis of activated CTL
Positive cells (%)
(Day) Stimulation CD3 CD4 CD8 CD16 CD25 IL-2R13
Case 5 (10) CD3 84.4 33.3 56.7 0.5 45.4 0.7
CD3 +FN 81.9 31.7 53.8 0.7 41.9 0.5
(21) CD3 98.4 75.6 20.5 0.4 57.3 0.8
CD3 + FN 94.5 73.6 24.7 0.3 62.0 0.5
Case9 (21) CD3 NT NT NT NT NT NT
CD3 +FN 97.5 80.9 17.8 0.02 65.2 0.21
Case8 (28) CD3 91.3 79.4 1.4 0.6 28.8 0.6
CD3 + FN 85.9 85.5 12.1 0.5 32.9 0.4
Case 13 (28) CD3 94.9 95.8 4.3 0.3 43.3 0.1
CD3 +FN 91.6 91.9 8.0 0.5 35.2 0.1
Case7 (42) CD3 NT NT NT NT NT NT
CD3 +FN 99.3 98.1 1.5 0.53 90.1 0.43
Case2 (42) CD3 NT NT NT NT NT NT
CD3 +FN 99.0 97.7 0.7 0.01 92.1 0.36
The phenotypes of the activated CTL were examined by flow cytometry in two gastric cancer (cases 2 and 5), one colonic cancer (case7), two
gallbladder cancer (cases 8 and 9) and one malignant methothelioma ofperitoneum (case 13). NT, not tested.
Table V MHC restriction and effector cells of CTL against autologous tumour cells
Autologous tumour-killing activity (% Cx)
Treatment of CTL E/T= 15 E/T=30
Media 11.6 14.9
Mouse IgG 11.3 14.9
Case7 Anti-CD4 3.1 5.8
(day42) Anti-CD8 10.6 14.7
Anti-HLA classI 2.7 9.2
Anti-HLA-DR 10.5 14.2
Media 8.5
Mouse IgG 7.6
Case 8 Anti-CD4 0.1
(day28) Anti-CD8 8.7
Anti-HLA classI 4.4
Anti-HLA-DR 8.1
Phenotypes of CTL activated by immobilised FN were determined by negative selection method employing
immunomagnetic beads separation. In blocking assay, 5pgmlr1 anti-HLA classI MAb or anti-HLA-DR MAb was
used. The autologous tumor-killing activity was determined by 4h5'Cr-release assay. CTL were induced fronipatients
with one colonic cancer (case7) and one gallbladder cancer (case8).
Table VI Cytokine production by CTL
IL-2 (pgmrl') IFN-y (pgml-') GM-CSF (pgml1) IL-4 (pgmrl') IL-6 (pgmrl')
FNstimulation (-) (+) (-) (+) (-) (+) (-) (+) (-) (+)
Case8 0 823 11 41 31 464 5 14 236 306
Case9 282 316 10 46 49 2156 11 97 135 158
Case 10 162 698 0 29 61 340 0 27 772 1362
Case 12 50 75 7 30 59 70 0 0 395 480
Case 13 318 380 1 8 714 3112 NT NT NT NT
Cytokine production by CTLwas measured. CTL were induced from the three patients with gallbladdercancer (cases 8- 10), one ovarian cancer
(case 12) and one malignant methothelioma ofperitoneum (case 13). Cytokine production including IL-2, IFN-y and GM-CSF was augmented by
FNstimulation (*P<0.05).
separation. The autologous tumour killing activity of these
CTLs was suppressed by the elimination of CD4+ cells.
These results indicate that CD4+ CTLs are strongly cytotoxic
against autologous tumour cells.
Cytokine activity produced by CTLs
The cytokine production by CTLs immediately after
AMLTC induced from five patients (three gallbladder
cancer, one ovarian cancer and one malignant methothelio-
ma of the peritoneum) was studied. As shown in Table VI
the cytokine production of CTLs was augmented by FN
stimulation. In particular, the production of IL-2, IFN-y and
GM-CSF was significantly augmented by FN stimulation
(P<0.05).
Discussion
Rosenberg et al. (1987, 1988) have reported that the therapy
with LAK cells and IL-2 showed 30% response in renal cell
cancer, reduced to 17% in follow-up studies, and TILs plusCD4+CTL stimulated by fibronectin
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IL-2 showed 50% response in melanoma, although long-term
follow-up to determine durability of response has not been
published.
We have reported the basic study of AIT using TILs
activated by IL-2 and IL-4 that exhibited high autologous
tumour killing activity and high proliferative response
(Yamaue et al., 1990; Tsunoda et al., 1992).
However, TILs cannot be induced in all cancer patients.
Therefore, we have chosen CTL induction by AMLTC to
overcome the problems of using TILs in AIT. Although AIT
using CTLs has been shown to be effective in clinical trials,
CTLs induced by AMLTC are not sufficiently proliferated by
IL-2 alone (Maeda et al., 1989; Aruga et al., 1991). We have
reported that CTLs can be sufficiently proliferated by
immobilised anti-CD3 MAb and IL-2 (Tani et al., 1995).
However, finding methods by which CTLs can be proliferated
more extensively is an important research area. The
extracellular matrix (ECM) is composed of a number of
macromolecules that promote cell adhesion, cell migration
and differentiation. Recently, ECM, such as FN, laminin and
collagen, has been reported to co-stimulate the DNA
synthesis of human PBLs (Shimizu et al., 1990; 1990;
Matsuyama et al., 1989). It has been reported that FN
induces AP-1 as an enhancer of IL-2 gene with signal
transduction of FN receptor (Yamada 1991).
Although FN alone has no ability to induce proliferation
of human PBLs, FN augments the proliferation of human
PBLs induced by immobilised anti-CD3 MAb, and the effect
of FN is stronger than any other ECM (Davis et al,. 1990;
Cardarelli et al., 1991). However, there has been no report of
FN on the proliferation and activation of CTLs induced by
AMLTC from cancer patients.
In the present study, we examined whether FN promotes
the proliferation and activation of CTLs generated by
immobilised anti-CD3 MAb and IL-2. DNA synthesis of
CTLs induced by AMLTC was augmented by immobilised
FN. Moreover, CTLs stimulated by immobilised FN showed
three or four times the proliferative response compared with
CTLs stimulated without FN in 3 weeks' culture. Since CTLs
induced by AMLTC are hard to proliferative by IL-2 alone,
the leukapheresis has been required to obtain PBMCs from
the cancer patients for AIT using CTLs (Aruga et al., 1991).
The present study indicates that CTLs can show marked
proliferation by the stimulation with immobilised FN.
Furthermore, for improvement of clinical efficacy, CTLs
are required to have higher autologous tumour killing
activity. In our present study, CTLs stimulated by
immobilised FN exhibited higher autologous tumour killing
activity than CTLs stimulated without FN. However,
cytotoxic activity against the NK-sensitive tumour cell line,
K562, or the NK-resistant tumour cell line, KATO-I1I, was
not augmented by FN stimulation. These results indicate that
the specific cytotoxic activity against autologous tumour cells
was augmented by FN stimulation.
We have reported that the surface phenotypes of CTLs
activated with immobilised anti-CD3 MAb and IL-2 were
predominantly CD3+ and CD4+ (Tani et al., 1995). In the
present study, CTLs activated with immobilised FN showed
more predominantly CD4+ T cells, and the autologous
tumour killing activity was suppressed by the elimination of
CD4+ CTLs.
Two types of mouse CD4+ Th cell clones differ in their
lymphokine production pattern (Mosmann et al., 1986). It
has been reported that the restricted cytokine profiles exist in
human CD4+ T-cell populations (Maggi et al., 1991). Thl
cells secrete IL-2, IFN-y and lymphotoxin, but they do not
secrete IL-4, IL-5 or IL-6. On the other hand, Th 2 cells
secrete IL-4, IL-5 and IL-6, but they do not produce IL-2,
IFN-y or lymphotoxin. Moreover, it has been reported that
Th 0 cells, which secreted a broad spectrum of cytokines,
including IL-2, IL-3, IL-4, IFN-y and TNF, were found
(Firestein et al., 1989; Mosmann et al., 1991). Since we
studied the cytokine production profiles in bulk culture
CTLs, not in CTL clones, we could not find the difference of
response between Thl, Th2 and ThO by FN stimulation.
However, immobilised FN up-regulated the production of IL-
2, IFN-y and GM-CSF in bulk culture. The results suggested
that FN might stimulate the activity of TH1 cells, and up-
regulated cytokine production might induce the strong
autologous tumour killing activity.
CTLs stimulated by IL-2 alone appear to be CD8+ cell
and MHC class I restricted, since their cytotoxicity has been
shown to be inhibited by anti-HLA class I MAb and by
elimination of CD8+ cells (Sato et al., 1986; Maeda et al.,
1989; Aruga et al., 1991; loannides et al., 1991). However, we
have reported that CD4+ CTLs generated by immobilised
anti-CD3 MAb and IL-2 are involved in the cytotoxicity
against autologous tumour cells and restricted by HLA-DR
(Tani et al., 1995). In the present study, we demonstrated that
CD4+ T cells activated with immobilised FN, were strongly
cytotoxic against autologous tumours, and restricted by HLA
class I, not by HLA-DR. Matsubayashi et al. (1989) have
demonstrated that the specific CD4+ CTL clone for Friend
virus-induced FBL-3 tumour cells is restricted by HLA class
I.
Moreover, in human systems, the auto-killing activity of
CD4+ CTL clone specific for human gastric cancer cells and
human melanoma cells is restricted by HLA class I (Itoh et
al., 1992; Wang et al., 1992). In the present study, we studied
the HLA restriction only in bulk culture CTLs. Further
studies are considered to be necessary to clarify the HLA-
restriction of CTLs stimulated by FN.
CD4+ T cells have been shown to be more susceptible to
immunosuppressive effects in the tumour-bearing state than
CD8+ T cells (Tada et al., 1990). Improving the
immunosuppressive state in cancer patients requires recovery
of helper function on CD4+ T cells. Therefore, infusing
CD4+ T cells, which have helper function, is essential in
improving the clinical efficacy in AIT for cancer patients.
Thus, our results indicate that immobilised FN promotes
the proliferation and the activation of CTLs, and FN-
activated CTLs might be effective for adoptive immunother-
apy in cancer patients.
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